PRCT logo

PROCEPT BioRobotics Corporation Stock Price

NasdaqGM:PRCT Community·US$1.9b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 21 Fair Values set on narratives written by author

PRCT Share Price Performance

US$32.92
-38.78 (-54.09%)
61.3% undervalued intrinsic discount
US$85.00
Fair Value
US$32.92
-38.78 (-54.09%)
62.4% undervalued intrinsic discount
US$87.50
Fair Value
Price US$32.92
AnalystHighTarget US$87.50
AnalystConsensusTarget US$65.60
AnalystLowTarget US$51.00

PRCT Community Narratives

AnalystHighTarget·
Fair Value US$85 59.1% undervalued intrinsic discount

Aging Population And Robotic Advances Will Unlock Urologic Potential

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value US$65.6 47.0% undervalued intrinsic discount

Clinical Adoption And Global Expansion Will Redefine Healthcare

0users have liked this narrative
0users have commented on this narrative
16users have followed this narrative
AnalystLowTarget·
Fair Value US$51 31.9% undervalued intrinsic discount

Competitive Pressures Will Hinder Urologic Procedures Yet Spur Progress

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent PRCT News & Updates

Is PROCEPT BioRobotics (NASDAQ:PRCT) A Risky Investment?

Sep 26
Is PROCEPT BioRobotics (NASDAQ:PRCT) A Risky Investment?

Procept BioRobotics: Increasing Average Selling Price, Initiate At Buy

Aug 14

What You Can Learn From PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S After Its 34% Share Price Crash

Aug 09
What You Can Learn From PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S After Its 34% Share Price Crash

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported, And Analysts Assigned A US$65.75 Price Target

Aug 08
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported, And Analysts Assigned A US$65.75 Price Target

US$77.00: That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After Its Latest Results

Apr 27
US$77.00: That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After Its Latest Results

Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects

Apr 18
Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects

PROCEPT BioRobotics Corporation Key Details

US$275.0m

Revenue

US$98.5m

Cost of Revenue

US$176.5m

Gross Profit

US$260.6m

Other Expenses

-US$84.1m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-1.51
Gross Margin
64.19%
Net Profit Margin
-30.60%
Debt/Equity Ratio
13.4%

PROCEPT BioRobotics Corporation Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Flawless balance sheet with limited growth.

1 Risk
1 Reward

About PRCT

Founded
2007
Employees
756
CEO
Larry Wood
WebsiteView website
www.procept-biorobotics.com

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. It also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

U.S. Market Performance

  • 7 Days: -2.8%
  • 3 Months: 5.3%
  • 1 Year: 13.4%
  • Year to Date: 11.7%
Over the last 7 days, the market has dropped 2.8%, driven by a decline of 2.5% in the Information Technology sector. In contrast to the last week, the market is actually up 13% over the past year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›